EA202090565A1 - Композиции и способы лечения диффузной в-крупноклеточной лимфомы - Google Patents

Композиции и способы лечения диффузной в-крупноклеточной лимфомы

Info

Publication number
EA202090565A1
EA202090565A1 EA202090565A EA202090565A EA202090565A1 EA 202090565 A1 EA202090565 A1 EA 202090565A1 EA 202090565 A EA202090565 A EA 202090565A EA 202090565 A EA202090565 A EA 202090565A EA 202090565 A1 EA202090565 A1 EA 202090565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
cell lymphoma
diffuse
treatment
Prior art date
Application number
EA202090565A
Other languages
English (en)
Inventor
Захари Зиммерман
Сяохун Алисия Чжан
Питер Кристофер Холланд
Джанет Франклин
Грегори Фрайберг
Original Assignee
Мерк Шарп энд Доум Корп.
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп энд Доум Корп., Амген Инк. filed Critical Мерк Шарп энд Доум Корп.
Publication of EA202090565A1 publication Critical patent/EA202090565A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

Предусмотрены способы и композиции для лечения диффузной B-крупноклеточной лимфомы (DLBCL) с использованием комбинации блинатумомаба и/или варианта блинатумомаба и пембролизумаба, варианта пембролизумаба и/или его антигенсвязывающего фрагмента.
EA202090565A 2017-10-13 2018-10-12 Композиции и способы лечения диффузной в-крупноклеточной лимфомы EA202090565A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13
PCT/US2018/055667 WO2019075366A1 (en) 2017-10-13 2018-10-12 COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS

Publications (1)

Publication Number Publication Date
EA202090565A1 true EA202090565A1 (ru) 2020-10-13

Family

ID=64110107

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090565A EA202090565A1 (ru) 2017-10-13 2018-10-12 Композиции и способы лечения диффузной в-крупноклеточной лимфомы

Country Status (15)

Country Link
US (1) US20200262919A1 (ru)
EP (1) EP3694520A1 (ru)
JP (2) JP2020536923A (ru)
KR (1) KR20200068655A (ru)
CN (1) CN111212646A (ru)
AU (1) AU2018347457A1 (ru)
BR (1) BR112020007203A2 (ru)
CA (1) CA3075291A1 (ru)
CL (1) CL2020000973A1 (ru)
EA (1) EA202090565A1 (ru)
IL (1) IL273805A (ru)
MX (1) MX2020003395A (ru)
SG (1) SG11202002374RA (ru)
TW (1) TW201922283A (ru)
WO (1) WO2019075366A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
WO2021183861A1 (en) * 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
CN100509850C (zh) 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
TR201816277T4 (tr) 2007-04-03 2018-11-21 Amgen Res Munich Gmbh Çapraz-tür-spesifik bağlama alanı.
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법

Also Published As

Publication number Publication date
SG11202002374RA (en) 2020-04-29
EP3694520A1 (en) 2020-08-19
CN111212646A (zh) 2020-05-29
US20200262919A1 (en) 2020-08-20
KR20200068655A (ko) 2020-06-15
CA3075291A1 (en) 2019-04-18
WO2019075366A1 (en) 2019-04-18
CL2020000973A1 (es) 2020-12-28
TW201922283A (zh) 2019-06-16
JP2024001071A (ja) 2024-01-09
MX2020003395A (es) 2020-08-03
BR112020007203A2 (pt) 2020-10-20
JP2020536923A (ja) 2020-12-17
AU2018347457A1 (en) 2020-04-09
IL273805A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CO2020015376A2 (es) Anticuerpos dirigidos contra il-11ra
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MD3582853T2 (ro) Compuși di-nucleotidici ciclici pentru tratamentul cancerului
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
JOP20200022A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201991818A1 (ru) Лечение рака
JOP20200023A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2020006297A (es) Variantes de cd19.
EA201890861A1 (ru) Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
MX2019011225A (es) Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
EA202090565A1 (ru) Композиции и способы лечения диффузной в-крупноклеточной лимфомы
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций